Clinical trials: Lung Cancer Patient
Lung Adenocarcinoma, Lung Adenosquamous Carcinoma
Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer
This randomized phase II trial studies how well erlotinib hydrochloride with or without carboplatin and paclitaxel works in treating patients with stage III-IV non-small cell lung cancer.
- Conditions
- Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Malignant Pericardial Effusion, Malignant Pleural Effusion
- Trial name
- NCT00126581
- Testing
- Carboplatin, Erlotinib, Erlotinib Hydrochloride
- Where
- 96 sites in United States
- Volunteers
- 188 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer
A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.
This 2 arm study will evaluate the management of Tarceva-induced skin rash in patients with non-small cell lung cancer who have failed first-line chemotherapy for advanced disease.
- Trial name
- NCT00531934
- Testing
- Doxycline, erlotinib [Tarceva]
- Where
- 24 sites in France
- Volunteers
- 147 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer
Randomized, Multi-center, Open-label, Study of PR104 Versus PR104/Docetaxel in Non-Small Cell Lung Cancer (NSCLC)
The current understanding of PR104 justifies the evaluation of PR104 with docetaxel in subjects with Non Small Cell Lung Cancer (NSCLC). These include: Aldo-keto reductase 1C3 (AKR1C3).
- Trial name
- NCT00862134
- Testing
- PR104, docetaxel, Granulocyte colony-stimulating factor
- Where
- 27 sites in United States, Canada and 1 more
- Volunteers
- 42 people
- Sponsor
- Proacta, Incorporated
Non-Squamous Non-Small Cell Lung Cancer
A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations
This single arm, open-label study will evaluate the efficacy and safety of erlotinib (Tarceva) in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)…
- Trial name
- NCT01260181
- Testing
- Erlotinib
- Where
- 9 sites in Portugal
- Volunteers
- 30 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer
Tarlox and Sotorasib in Patients With KRAS G12C Mutations
This is a Phase IB dose expansion trial with safety lead-in evaluating the safety, clinical activity/efficacy of the combination of tarloxotinib and sotorasib in patients with KRAS G12C mutation who have progressed on any small…
- Trial name
- NCT05313009
- Testing
- Sotorasib and Tarloxotinib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Medical University of South Carolina
Cachexia
Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas
A safety \& efficacy clinical study of the investigational medicinal product BYM338 for the treatment of unintentional weight loss in patients with cancer of the lung or the pancreas
- Trial name
- NCT01433263
- Testing
- BYM338 active drug
- Where
- 10 sites in United States, Lithuania and 3 more
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Colorectal Cancer, Lung Cancer
QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA
The purpose of this study is to find out what effects (good and bad) that a cancer vaccine has on you and your cancer. The cancer vaccine is called Ad5 [E1-, E2b-]-CEA(6D)or ETBX-011 and is made by Etubics.
- Conditions
- Colorectal Cancer, Lung Cancer, Breast Cancer, Prostate Cancer
- Trial name
- NCT01147965
- Testing
- Ad5 CEA Vaccine
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- NantCell, Inc.
Non Small Cell Lung Cancer
Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR
This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer.
- Trial name
- NCT01854034
- Testing
- AUY922
- Where
- 4 sites in United States
- Volunteers
- 29 people
- Sponsor
- Massachusetts General Hospital
Non Small Cell Lung Cancer
First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin
The research study is testing the investigational drug necitumumab (IMC-11F8) in the treatment of advanced non-small cell lung cancer.
- Trial name
- SQUIRE (NCT00981058)
- Testing
- Necitumumab, Gemcitabine, Cisplatin
- Where
- 182 sites in United States, Australia and 24 more
- Volunteers
- 1,093 people
- Sponsor
- Eli Lilly and Company
Non-small Cell Lung Cancer
Retrospective Epidemiology Study Of ALK Rearrangement In Non-Small Cell Lung Cancer Patients In The Middle East & North Africa
Thet study aims to estimate the prevalence of ALK rearrangement in the Middle East North Africa population by using the Ventana ALK-IHC method for ALK protein detection in retrospective NSCLC clinical samples, \& to evaluate the…
- Trial name
- ALK NSCLC MENA (NCT02304406)
- Where
- 11 sites in Egypt, Lebanon and 3 more
- Volunteers
- 449 people
- Sponsor
- Pfizer
Non-Small Cell Lung Cancer
A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
This is a Phase 2, multicenter study designed to evaluate the efficacy and safety of trastuzumab emtansine administered as a single-agent in participants with HER2-positive (HER2 IHC 2+ or HER2 IHC 3+) advanced or metastatic…
- Trial name
- NCT02289833
- Testing
- Trastuzumab Emtansine
- Where
- 23 sites in United States, Germany and 5 more
- Volunteers
- 49 people
- Sponsor
- Hoffmann-La Roche
Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer
Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib
This phase I/Ib trial studies the side effects and best dose of pembrolizumab when given together with afatinib dimaleate in treating patients with non-small cell lung cancer that has spread to other places in the body and…
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
- Trial name
- NCT02364609
- Testing
- Afatinib Dimaleate, Pembrolizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Jonathan Riess
Non-Small Cell Lung Cancer, Lung Cancer
TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
The goal of this clinical research study is to find out if erlotinib given with chemotherapy and radiation therapy can help to control NSCLC. The safety of this combination treatment will also be studied.
- Trial name
- NCT00563784
- Testing
- Erlotinib, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- M.D. Anderson Cancer Center
Colon Cancer, Head and Neck Cancer
Positron Emission Tomography/Magnetic Resonance Imaging in Patients
This clinical trial studies positron emission tomography (PET)/magnetic resonance imaging (MRI) in patients undergoing PET/computed tomography (CT).
- Conditions
- Colon Cancer, Head and Neck Cancer, Lung Cancer, Lymphoma
- Trial name
- NCT01557881
- Testing
- magnetic resonance imaging with positron emission tomography scanning
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Case Comprehensive Cancer Center
Advanced Lung Cancer
CAR-T Cell Immunotherapy for Advanced Lung Cancer
The NSCLC patients who failed the standard treatments, with positive Programmed Death-Ligand 1 (PD-L1) expression, were enrolled into this trial. About 22 advanced NSCLC patients will be screened according to the criteria.
- Trial name
- NCT03330834
- Testing
- CAR-T cells to treat advanced lung cancer
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Sun Yat-sen University
Advanced Nonhematological Malignancies, Non-Small Cell Lung Cancer
Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies
This is an open-label, multicenter study with a phase 1 dose escalation portion and a 2-stage, phase 2 portion, investigating MLN8237 (alisertib) in patients with advanced nonhematological malignancies.
- Conditions
- Advanced Nonhematological Malignancies, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer
- Trial name
- NCT01045421
- Testing
- MLN8237 (Alisertib)
- Where
- 2 sites in United States
- Volunteers
- 273 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Carcinoma, Non-Small-Cell Lung
Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy
To determine the appropriateness of the dose of nintedanib 200 mg b.i.d. plus docetaxel 75 mg/m2 as starting dose by evaluating the safety in Japanese patients with body surface area (BSA) <1.5 m2 and locally advanced or…
- Trial name
- NCT02300298
- Testing
- Nintedanib, Docetaxel
- Where
- 6 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Boehringer Ingelheim
Lung Cancer, Solid Tumor (Not Breast or Prostate Cancers)
Cabozantinib in Advanced Solid Malignancies
This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer.
- Trial name
- NCT01588821
- Testing
- Cabozantinib
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Massachusetts General Hospital
Advanced Malignant Solid Neoplasm, Recurrent Ependymoma
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well larotrectinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with NTRK fusions that may have spread from where it first started to…
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Glioma
- Trial name
- NCT03213704
- Testing
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan
- Where
- 124 sites in United States, Puerto Rico
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer
Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer
The purpose of this study is to determine the recommended phase 2 dose (RP2D) of TAK-117 when administered in combination with docetaxel in participants with non-small cell lung cancer (NSCLC) and to evaluate efficacy, safety…
- Trial name
- NCT02393209
- Testing
- Docetaxel, TAK-117
- Where
- 11 sites in United States, Canada and 1 more
- Volunteers
- 14 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.